Document:

Exhibit 10.1

 

FIRST AMENDMENT TO AMENDED AND RESTATED EMPLOYMENT
AGREEMENT

 

This First Amendment to
Amended and Restated Employment Agreement (“Amendment”), dated April 27, 2022 and effective as of the same date,
unless otherwise set forth below, is entered into by and between 180 Life Sciences Corp., a Delaware corporation (the
“Company”), and James N. Woody (“Executive”) (collectively, the Company and Executive are the
“Parties”).

 

WHEREAS, the Company
and Executive have entered into an Amended and Restated Employment Agreement, dated made as of February 24, 2021, and effective November
6, 2020 (the “Agreement”)1, concerning
the employment of Executive as Chief Executive Officer of the Company;

 

WHEREAS, certain capitalized
terms used below have the meanings given to such terms in the Agreement; and

 

WHEREAS, the parties
wish to amend the Agreement to revise certain terms of the Agreement as set forth herein in order to reduce Company costs on a temporary
basis.

 

NOW, THEREFORE, in
consideration of the mutual covenants and agreements hereinafter set forth, the receipt and sufficiency of which is hereby acknowledged
and confirmed, the parties hereto agree as follows:

 

		1.	Effective January 1, 2022, the Base Salary of $450,000 is amended to increase such amount by 3% (the “Increase
in Salary”) and effective March 1, 2022, the Base Salary is reduced by $92,700 (a 20% reduction) and such amounts (the “Accrued
Amounts”) shall be accrued until such time as the Board of Directors determines to pay such Accrued Amounts, whhas sufficient
cash on hand to pay such Accrued Amounts, which the Company expects will not be until it has raised a minimum of $15,000,000 (the “Funding
Determination Date”); and

 

		2.	$370,800 of such Base Salary shall be payable per the payroll practices of the Company in cash by the
Company starting effective March 1, 2022 until the Funding Determination Date

 

		3.	On the Funding Determination Date, Executive’s salary shall increase to the Base Salary taking into
account the Increase in Salary (with no accrual) and the Accrued Amounts shall be paid by the Company. In addition, at the discretion
of the Board of the Directors, the Base Salary on the Funding Determination Date may be further increased by 2%.

 

		4.	Except to the extent modified hereby, the Agreement shall remain in full force and effect.

 

		5.	This Amendment shall be binding upon and inure to the benefit of the parties and their successors and
assigns.

 

		6.	This Agreement and any signed agreement or instrument entered into in connection with this Agreement,
and any amendments hereto or thereto, may be executed in one or more counterparts, all of which shall constitute one and the same instrument.
Any such counterpart, to the extent delivered by means of a facsimile machine or by .pdf, .tif, .gif, .jpeg or similar attachment to electronic
mail (any such delivery, an “Electronic Delivery”) shall be treated in all manner and respects as an original executed
counterpart and shall be considered to have the same binding legal effect as if it were the original signed version thereof delivered
in person.

 

 

		1	https://www.sec.gov/Archives/edgar/data/1690080/000121390021013180/ea136864ex10-2_180lifesci.htm

 

     

     

    

 

IN WITNESS WHEREOF,
the parties have caused the Amendment to be executed as of the date and year first referenced above.

 	The “Company”	180 Life Sciences Corp.
	 	 	 
	Date: April 27, 2022	By: 	/s/ Ozan Pamir
	 	Its:	CFO
	 	Printed Name:	 

                                                 Ozan Pamir

	 	 	 
	The “Executive”	 	 
	Date: April 16, 2022	By: 	/s/ James N. Woody
	 		James N. WoodyExhibit 10.2

 

FIRST AMENDMENT TO EMPLOYMENT AGREEMENT

 

This First Amendment to
Employment Agreement (“Amendment”), dated April 27, 2022 and effective as of the same date, unless otherwise set
forth below, is entered into by and between 180 Life Sciences Corp., a Delaware corporation (the “Company”), and
Quan Vu (“Executive”) (collectively, the Company and Executive are the “Parties”).

 

WHEREAS, the Company
and Executive have entered into an Employment Agreement, dated October 29, 2021, and effective November 1, 2021 (the “Agreement”)1,
concerning the employment of Executive as Chief Operating Officer and Chief Business Officer of the Company;

 

WHEREAS, certain capitalized
terms used below have the meanings given to such terms in the Agreement; and

 

WHEREAS, the parties
wish to amend the Agreement to revise certain terms of the Agreement as set forth herein in order to reduce Company costs on a temporary
basis.

 

NOW, THEREFORE, in
consideration of the mutual covenants and agreements hereinafter set forth, the receipt and sufficiency of which is hereby acknowledged
and confirmed, the parties hereto agree as follows:

 

		1.	Effective January 1, 2022, the Base Salary of $390,000 is amended to increase such amount by 3% (the “Increase
in Salary”) and effective March 1, 2022, the Base Salary is reduced by $80,340 (a 20% reduction) and such amounts (“Accrued
Amounts”) shall be accrued until such time as the Board of Directors determines to pay such Accrued Amounts, which the Company expects
will not be until it has raised a minimum of $15,000,000 (the “Funding Determination Date”);

 

		2.	$321,360 of such Base Salary shall be payable per the payroll practices of the Company in cash by the
Company starting effective March 1, 2022 until the Funding Determination Date.

 

		3.	On the Funding Determination Date, Executive’s salary shall increase to the Base Salary taking into
account the Increase in Salary (with no accrual) and the Accrued Amounts shall be paid by the Company. In addition, at the discretion
of the Board of the Directors, the Base Salary on the Funding Determination Date may be further increased by 2%.

 

		4.	Except to the extent modified hereby, the Agreement shall remain in full force and effect.

 

		5.	This Amendment shall be binding upon and inure to the benefit of the parties and their successors and
assigns.

 

		6.	This Agreement and any signed agreement or instrument entered into in connection with this Agreement,
and any amendments hereto or thereto, may be executed in one or more counterparts, all of which shall constitute one and the same instrument.
Any such counterpart, to the extent delivered by means of a facsimile machine or by .pdf, .tif, .gif, .jpeg or similar attachment to electronic
mail (any such delivery, an “Electronic Delivery”) shall be treated in all manner and respects as an original executed
counterpart and shall be considered to have the same binding legal effect as if it were the original signed version thereof delivered
in person.

 

 

		1	https://www.sec.gov/Archives/edgar/data/0001690080/000121390021055978/ea149725ex10-1_180life.htm

 

     

     

    

 

IN WITNESS WHEREOF,
the parties have caused the Amendment to be executed as of the date and year first referenced above.

 

	The “Company”	180 Life Sciences Corp.
	 	 	 
	Date: April 27, 2022	By: 	/s/ Ozan Pamir
	 	Its:	CFO
	 	Printed Name:	 

                                                 Ozan Pamir

	 	 	 
	The “Executive”	 	 
	Date: April 15, 2022	By: 	/s/ Quan Vu
	 		Quan VuExhibit 10.3

 

FIRST AMENDMENT TO EMPLOYMENT AGREEMENT

 

This First Amendment to
Employment Agreement (“Amendment”), dated April 27, 2022 and effective as of the same date, unless otherwise set
forth below, is entered into by and between 180 Life Sciences Corp., a Delaware corporation (the “Company”), and
Jonathan Rothbard (“Executive”) (collectively, the Company and Executive are the
“Parties”).

 

WHEREAS, the Company
and Executive have entered into an Employment Agreement, dated August 21, 2019, and effective November 6, 2020 (the “Agreement”)1,
concerning the employment of Executive as Chief Scientific Officer of the Company;

 

WHEREAS, certain capitalized
terms used below have the meanings given to such terms in the Agreement; and

 

WHEREAS, the parties
wish to amend the Agreement to revise certain terms of the Agreement as set forth herein in order to reduce Company costs on a temporary
basis.

 

NOW, THEREFORE, in
consideration of the mutual covenants and agreements hereinafter set forth, the receipt and sufficiency of which is hereby acknowledged
and confirmed, the parties hereto agree as follows:

 

		1.	Effective January 1, 2022, the Base Salary of $375,000 is amended to increase such amount by 3% (the “Increase
in Salary”) and effective March 1, 2022, the Base Salary is reduced by $96,562.50 (a 25% reduction) and such amounts (“Accrued
Amounts”) shall be accrued until such time as the Board of Directors determines to pay such Accrued Amounts, which the Company expects
will not be until it has raised a minimum of $15,000,000 (the “Funding Determination Date”);

 

		2.	$289,687.50 of such Base Salary shall be payable per the payroll practices of the Company in cash by the
Company starting effective March 1, 2022 until the Funding Determination Date.

 

		3.	On the Funding Determination Date, Executive’s salary shall increase to the Base Salary taking into
account the Increase in Salary (with no accrual) and the Accrued Amounts shall be paid by the Company. In addition, at the discretion
of the Board of the Directors, the Base Salary on the Funding Determination Date may be further increased by 2%.

 

		4.	Any future increases to salary will be determined on an annual basis by the Company’s board of directors
at the recommendation of the Compensation Committee, and the annual 10% increases provided in the Agreement shall be overridden by such
future determinations by the board of directors.

 

		5.	Except to the extent modified hereby, the Agreement shall remain in full force and effect.

 

		6.	This Amendment shall be binding upon and inure to the benefit of the parties and their successors and
assigns.

 

		7.	This Agreement and any signed agreement or instrument entered into in connection with this Agreement,
and any amendments hereto or thereto, may be executed in one or more counterparts, all of which shall constitute one and the same instrument.
Any such counterpart, to the extent delivered by means of a facsimile machine or by .pdf, .tif, .gif, .jpeg or similar attachment to electronic
mail (any such delivery, an “Electronic Delivery”) shall be treated in all manner and respects as an original executed
counterpart and shall be considered to have the same binding legal effect as if it were the original signed version thereof delivered
in person.

 

 

	1	https://www.sec.gov/Archives/edgar/data/0001690080/000121390021036392/f10k2020ex10-44_180lifescien.htm

 

    

     

    

 

IN WITNESS WHEREOF,
the parties have caused the Amendment to be executed as of the date and year first referenced above.

 

	The “Company”	180 Life
    Sciences Corp.
	 	 	 
	Date:
    April 27, 2022	By:  	/s/ Ozan Pamir
	 	Its:	CFO 
	 	Printed	 
	 	Name:	Ozan Pamir
	 	 	 
	The “Executive”	 	 
	Date:
    April 15, 2022	By:  	 /s/
    Jonathan Rothbard
	 	 	Jonathan
    Rothbard

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00344-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00344-of-00352.parquet"}], [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00344-of-00352.parquet"}]]